Erratum: Agreement between fasting and postprandial LDL cholesterol measured with 3 methods in patients with type 2 diabetes mellitus (Clinical Chemistry (2011), 57 (298-308) DOI: 10.1373/clinchem.2009.133868);Agreement between fasting and postprandial LDL cholesterol measured with 3 methods in patients with type 2 diabetes mellitus

Clinical Chemistry

Volumn 57, Issue 2, 2011, Pages 298-308

  Lund, Søren S ^a   Petersen, Martin ^b   Frandsen, Merete ^a   Smidt, Ulla M ^a   Parving, Hans Henrik ^c,d   Vaag, Allan A ^a,e   Jensen, Tonny ^a,c  

^a STENO DIABETES CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

^e LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CONCENTRATION (PARAMETERS); DIET RESTRICTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE;

EID: 79551562610     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.164392     Document Type: Erratum

References (55)

1. Grundy SM, Becker D, Clark LT, Cooper RS, Denke MA, Howard J, et al. Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation 2002;106: 3143-421.
2. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines 1. Circulation 2004;110:227-39.
3. Rosenzweig JL, Ferrannini E, Grundy SM, Haffner SM, Heine RJ, Horton ES, Kawamori R. Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2008;93:3671-89.
4. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008;31: 811-22.
5. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008;118:2047-56.
6. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008;118:993-1001.
7. Lund SS, Vaag AA, Jensen T. Letter by Lund et al regarding article, "Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events." Circulation 2009; 119:e384.
8. Mora S, Buring JE, Ridker PM, Rifai N. Response to letter regarding article, "Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events." Circulation 2009;119:e385.
9. Nordestgaard BG, Benn M. Fasting and nonfasting LDL cholesterol: to measure or calculate? Clin Chem 2009;55:845-7.
10. Mora S, Rifai N, Buring JE, Ridker PM. Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem 2009;55:888-94.
11. Redberg RF, Benjamin EJ, Bittner V, Braun LT, Goff DC Jr, Havas S, et al. ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiovascular Disease) developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research. J Am Coll Cardiol 2009;54:1364-405.
12. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2007;28:2375-414.
13. Bachorik PS, Ross JW. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin Chem 1995;41:1414-20.
14. Nordestgaard BG, Hilsted L, Stender S. Plasma lipids in non-fasting patients and signal values of laboratory results [in Danish]. Ugeskr laeger 2009;171:1093.
15. The Emerging Risk Factors Collaboration: major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
16. BBC News. 'No fasting' for cholesterol test. http://news.bbc.co.uk/go/pr/ fr/-/2/hi/health/8353510.stm (Accessed November 2009).
17. Wilder LB, Bachorik PS, Finney CA, Moy TF, Becker DM. The effect of fasting status on the determination of low-density and high-density lipoprotein cholesterol. Am J Med 1995;99: 374-7.
18. Rifai N, Merrill JR, Holly RG. Postprandial effect of a high fat meal on plasma lipid, lipoprotein cholesterol and apolipoprotein measurements. Ann Clin Biochem 1990;27(Pt 5):489-93.
19. Cohn JS, McNamara JR, Schaefer EJ. Lipoprotein cholesterol concentrations in the plasma of human subjects as measured in the fed and fasted states. Clin Chem 1988;34:2456-9.
20. Attia N, Durlach V, Paul JL, Soni T, Betoulle D, Girard-Globa A. Modulation of low density lipoprotein subclasses by alimentary lipemia in control and normotriglyceridemic non-insulin-dependent diabetic subjects. Atherosclerosis 1995;113:197-209.
21. Schaefer EJ, Audelin MC, McNamara JR, Shah PK, Tayler T, Daly JA, et al. Comparison of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease. Am J Cardiol 2001;88:1129-33.
22. Nauck M, Graziani MS, Bruton D, Cobbaert C, Cole TG, Lefevre F, et al. Analytical and clinical performance of a detergent-based homogeneous LDL-cholesterol assay: a multicenter evaluation. Clin Chem 2000;46:506-14.
23. Weiss R, Harder M, Rowe J. The relationship between nonfasting and fasting lipid measurements in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Ther 2003;25:1490-7.
24. Dungan KM. A comparison of lipid and lipoprotein measurements in the fasting and nonfasting states in patients with type 2 diabetes. Curr Med Res Opin 2007;23:2689-95.
25. Leary ET, Wang T, Baker DJ, Cilla DD, Zhong J, Warnick GR, et al. Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasma. Clin Chem 1998;44:2490-8. (Pubitemid 28565661)
26. Miller WG, Waymack PP, Anderson FP, Ethridge SF, Jayne EC. Performance of four homogeneous direct methods for LDL-cholesterol. Clin Chem 2002;48:489-98.
27. Okada M, Matsui H, Ito Y, Fujiwara A, Inano K. Low-density lipoprotein cholesterol can be chemically measured: a new superior method. J Lab Clin Med 1998;132:195-201. (Pubitemid 28422255)
28. Schindhelm RK, Alssema M, Scheffer PG, Diamant M, Dekker JM, Barto R, et al. Fasting and post-prandial glycoxidative and lipoxidative stress are increased in women with type 2 diabetes. Diabetes Care 2007;30:1789-94.
29. Lund SS, Petersen M, Frandsen M, Smidt UM, Parving H-H, Vaag AA, Jensen T. Sustained post-prandial decrease in plasma levels of LDL cholesterol in patients with type-2 diabetes mellitus. Scand J Clin Lab Invest 2008;68:628-40.
30. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;327:307-10.
31. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-53.
32. Bachorik PS. Measurement of low-density-lipoprotein cholesterol. In: Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of lipoprotein testing. Washington, DC: AACC Press, 2000; 245-63.
33. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifugation. Clin Chem 1972; 18:499-502.
34. Faas FH, Earleywine A, Smith G, Simmons DL. How should low-density lipoprotein cholesterol concentration be determined? J Fam Pract 2002; 51:972-5.
35. Nauck M, Warnick GR, Rifai N. Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem 2002;48:236-54.
36. Rivellese AA, De-Natale C, Di-Marino L, Patti L, Iovine C, Coppola S, et al. Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels. J Clin Endocrinol Metab 2004;89:2153-9.
37. Iovine C, Vaccaro O, Gentile A, Romano G, Pisanti F, Riccardi G, Rivellese AA. Post-prandial triglyceride profile in a population-based sample of type 2 diabetic patients. Diabetologia 2004;47:19-22.
38. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46:733-49.
39. Rifai N, Warnick GR. Quality specifications and the assessment of the biochemical risk of atherosclerosis. Clin Chim Acta 2004;346:55-64. (Pubitemid 38952690)
40. Esteban-Salan M, Guimon-Bardesi A, de la Viuda-Unzueta JM, Azcarate-Ania MN, Pascual-Usandizaga P, Amoroto-Del-Rio E. Analytical and clinical evaluation of two homogeneous assays for LDL-cholesterol in hyperlipidemic patients. Clin Chem 2000;46:1121-31. (Pubitemid 30643314)
41. Miller WG, Myers GL, Sakurabayashi I, Bachman LM, Caudill SP, Dziekonski A, et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem 2010;56: 977-86.
42. Lund SS, Tarnow L, Stehouwer CD, Schalkwijk CG, Frandsen M, Smidt UM, et al. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. Diabetes Obes Metab 2007;9:394-407.
43. Lund SS, Tarnow L, Frandsen M, Smidt UM, Pedersen O, Parving HH, Vaag AA. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes. Eur J Endocrinol 2008;158:35-46; Erratum: 2008;158:443-5.
44. Stöckl D, Rodriguez-Cabaleiro D, Van-Uytfanghe K, Thienpont LM. Interpreting method comparison studies by use of the Bland-Altman plot: reflecting the importance of sample size by incorporating confidence limits and predefined error limits in the graphic. Clin Chem 2004;50:2216-8.
45. Brown H, Prescott R. Applied mixed models in medicine, 2nd ed. West Sussex, UK: Wiley & Sons, 2006.
46. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326:1423-7.
47. Linsel-Nitschke P, Götz A, Erdmann J, Braenne I, Braund P, Hengstenberg C, et al. Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease: a Mendelian randomisation study. PLoS ONE 2008;3:e2986.
48. 2+ method. Clin Chem 1998;44:1242-50.
49. Yu HH, Markowitz R, De Ferranti SD, Neufeld EJ, Farrow G, Bernstein HH, Rifai N. Direct measurement of LDL-C in children: performance of two surfactant-based methods in a general pediatric population. Clin Biochem 2000;33:89-95.
50. de Ferranti S, Shapiro D, Markowitz R, Neufeld E, Rifai N, Bernstein H. Nonfasting low-density lipoprotein testing: utility for cholesterol screening in pediatric primary care. Clin Pediatr (Phila) 2007;46:441-5.
51. Kim M, Suk J, Kim H, Jung H, Kim T, Park J. Post-prandial lipid levels for assessing target goal achievement in type 2 diabetic patients taking statin. J Korean Med Sci 2010;25:387-92.
52. Warnick GR, Knopp RH, Fitzpatrick V, Branson L. Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin Chem 1990;36:15-9. (Pubitemid 20042158)
53. Roche Diagnostics. LDL-C plus product profile and package insert. 1998.
54. Esteban-Salan M, Aguilar-Doreste JA, Arranz-Pena ML, Juve-Cuxart S, Gich-Salarich I, Zapico-Muniz E, Ordonez-Llanos J. Multicentric evaluation of the homogeneous LDL-cholesterol Plus assay: comparison with beta-quantification and Friedewald formula. Clin Biochem 2008;41: 1402-9.
55. Cole TG, Klotzsch SG, McNamara JR. Measurement of triglyceride concentration. In: Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of lipoprotein testing. Washington, DC: AACC Press, 2000;207-19.